Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644598 · ClinicalTrials.gov registry record · Phase 2
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
A Phase 2 study, sponsored by Georgetown University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT07644598 is a Phase 2 study that has not yet begun recruiting, run by Georgetown University. The registered enrollment target is 58 participants.
The verdict
NCT07644598, a Phase 2 study, has not yet begun recruiting, sponsored by Georgetown University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer. The main question it aims to answer is: Is microboost SBRT with whole gland de-escalation both safe and effective in managing patients with low to intermediate-risk prostate cancer while maintaining acceptable toxicity levels? All patients will receive microboost SBRT at a dose of 45 Gy delivered in 5 fractions in up to 4 MRI-defined lesions. Patients (Arm 1) with highest grade disease in the microboost target lesion in the absence of GG2-3 beyond the microboost target (only GG1 disease can be present outside of the microboost region) will receive whole gland de-escalation at a dose of 30 Gy delivered in 5 fractions. Patients (Arm 2) with highest grade disease outside of the target lesion will receive whole gland de-escalation at a dose of 35 Gy delivered in 5 fractions. Participants will be treated every other day over a two week period and then follow up after radiation treament for up to 5 years. Participants will be asked to complete questionnaires and provide blood and urine samples for research purposes.
Interventions
- RADIATION Microboost SBRT
- RADIATION Whole gland de-escalation 30 Gy
- RADIATION Whole gland de-escalation 35 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2026-09 |
| Est. Completion | 2035-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07644598
The ClinicalTrials.gov registry entry for NCT07644598 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Microboost SBRT is the first listed.
NCT07644598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07644598 about?
NCT07644598 is a clinical study titled "MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer". The goal of this clinical trial is to determine the safety of stereotactic body radiation therapy (SBRT) microboost technique in patients with low to intermediate risk prostate cancer. The main question it aims to answer is: Is microboost SBRT with whole gland de-escalation both safe and effective i...
What is the current status of trial NCT07644598?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2026-09. Estimated completion is 2035-01.
What interventions are being tested in trial NCT07644598?
The interventions under investigation include: Microboost SBRT (RADIATION), Whole gland de-escalation 30 Gy (RADIATION), Whole gland de-escalation 35 Gy (RADIATION).
Who is sponsoring clinical trial NCT07644598?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.